Literature DB >> 25602963

Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data.

G P Rubin1, C L Saunders2, G A Abel2, S McPhail3, G Lyratzopoulos2, R D Neal4.   

Abstract

BACKGROUND: For patients with symptoms of possible cancer who do not fulfil the criteria for urgent referral, initial investigation in primary care has been advocated in the United Kingdom and supported by additional resources. The consequence of this strategy for the timeliness of diagnosis is unknown.
METHODS: We analysed data from the English National Audit of Cancer Diagnosis in Primary Care on patients with lung (1494), colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer relating to the ordering of investigations by the General Practitioner and their nature. Presenting symptoms were categorised according to National Institute for Health and Care Excellence (NICE) guidance on referral for suspected cancer. We used linear regression to estimate the mean difference in primary-care interval by cancer, after adjustment for age, gender, and the symptomatic presentation category.
RESULTS: Primary-care investigations were undertaken in 3198/5036 (64%) of cases. The median primary-care interval was 16 days (IQR 5-45) for patients undergoing investigation and 0 days (IQR 0-10) for those not investigated. Among patients whose symptoms mandated urgent referral to secondary care according to NICE guidelines, between 37% (oesophagus) and 75% (pancreas) were first investigated in primary care. In multivariable linear regression analyses stratified by cancer site, adjustment for age, sex, and NICE referral category explained little of the observed prolongation associated with investigation.
INTERPRETATION: For six specified cancers, investigation in primary care was associated with later referral for specialist assessment. This effect was independent of the nature of symptoms. Some patients for whom urgent referral is mandated by NICE guidance are nevertheless investigated before referral. Reducing the intervals between test order, test performance, and reporting can help reduce the prolongation of primary-care intervals associated with investigation use. Alternative models of assessment should be considered.

Entities:  

Mesh:

Year:  2015        PMID: 25602963      PMCID: PMC4333492          DOI: 10.1038/bjc.2014.634

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


There are an estimated 300 million consultations in general practice in England annually (90% of all patient contacts with health care) (Hippisley-Cox and Vinogradova, 2009). A major challenge for primary-care clinicians is to discriminate, often on the basis of undifferentiated or non-specific symptoms, between patients with self-limiting illness and those with significant disease. Cancer symptoms typically have low positive predictive values and present a particular challenge in this respect (Hamilton, 2009). Nevertheless, prompt identification and referral for investigation of patients with suspected cancer is a major public and policy concern (Department of Health, 2007; Macmillan Cancer Support, 2014), based on a widely held view that delays have a detrimental effect on outcome. The evidence is not as yet definitive. Although some studies have shown an association between longer time to diagnosis and poorer clinical outcomes (Richards ; Torring ), confounding by patients with advanced disease at presentation can make their interpretation problematic (Neal, 2009). Meanwhile, prolonged time to diagnosis results in psychological distress and sub-optimal patient experience (Risberg ; Rarer Cancer Foundation, 2011). Clinical guidance for general practitioners (GPs) on high-risk features warranting urgent referral for suspected cancer has been produced in a number of countries, and in England by NICE in 2005 (National Institute for Health and Care Excellence (2005)). Many cancer patients, however, present to their GP with lower-risk features (Hamilton, 2010). A more recent approach to improving cancer outcomes in England has been to increase access for GPs to diagnostic tests supported by guidance on their use (Department of Health, 2012a). In the 3 months before diagnosis, Danish patients with cancer have around 10 times as many diagnostic investigations as the reference population, some instigated by GPs (Christensen ). Most studies of GPs' use of investigations has addressed issues of test use (Jellema ) and efficiency (Verstappen ; Schoen ). It is uncertain, however, whether initial investigation of cancer symptoms in primary care delays referral for specialist assessment. This question is central to clinical practice and cancer diagnosis. In order to answer the question of whether, in patients with symptoms suggestive of cancer, primary-care investigations are associated with less prompt referral, we analysed data from the English National Audit of Cancer Diagnosis in Primary Care, conducted during 2009/10 and containing information on 18 879 patients diagnosed with cancer in that period (Rubin ).

Patients and methods

The methods used in collection of the source data are described in detail elsewhere (Rubin ). In brief, anonymous data were collected by GPs or other primary-care professionals in an estimated total of 1170 general practices (∼14% of all practices in England) that participated voluntarily in an audit of cancer diagnosis in primary care. All patients of those practices, who were diagnosed with cancer, typically during a defined period of up to 12 months, were included in the audit. Patients with screen-detected cancer, in situ cancer, and non-melanoma skin cancer were excluded. The age, gender, and cancer diagnosis case-mix of the audited population is representative of the population-based cancer incidence statistics, and participating practices are similar to non-participating practices in their (former) cancer networks (Lyratzopoulos ). We analysed data on patients with lung (1494), colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer. These six cancer sites were selected because they each have a range of presenting symptoms from high to low risk, and because for each there is one or more investigation that may be appropriately ordered as part of the patient's assessment in primary care and that is generally available to GPs in England. We analysed data on patients aged 15 years or older with completely observed information on primary-care interval values from 0 to 730 days (Lyratzopoulos ). We defined primary-care interval as the period in days from first presentation to a GP with a relevant symptom to the date of first specialist referral for further assessment. The audit also collected the date of the first appointment with a specialist, but did not collect the date of diagnosis. Gender and age were recorded from the patient medical records, the latter categorised for this study into six groups 15–44, 45–54, 55–64, 65–74, 75–4 and 85+. Data were extracted from the audit data set in relation to two questions ‘Did the GP order any investigations' and ‘If yes, please list the investigations in order'. Practice staff were asked to identify any investigations undertaken prior to referral. Responses to the first question were coded as yes, no, or missing, and responses to the second question were used to create five binary variables coding whether or not the patient had had any of five common investigations: blood test; chest X-ray; ultrasound scan; CT or MRI scan; endoscopic investigation.

Clinical presentation

Free text audit records in response to the question ‘What was the main presenting symptom?' were categorised in two stages. First, and separately by cancer, the presenting symptom(s) was classified into between 20 and 37 groups (Appendix Table A1). These were agreed by three clinicians (GPR, RDN, GL) and then independently assigned by them. Disagreements were resolved by discussion between coders. Where more than one symptom was described, the main symptom was taken as the first stated, unless a NICE Clinical Guideline (CG)27-mandated (‘alarm') symptom appeared later in the list. Second, patients were classified on the basis of their presenting symptom(s) and age into five groups according to CG27; mandated referral; possibly mandated referral (insufficient information provided on qualifying conditions (e.g., severity, duration, frequency) to be definitive); mandated investigation; possibly mandated investigation (as above); no mandated action. Some presenting symptoms (e.g., ascites, haematemesis) were not specifically mentioned in CG27 as requiring urgent referral, but the clinical consensus was that this would be best practice. These were included in the ‘mandated referral' group. Coding was age specific for those symptoms for which CG27 recommendations were age-conditional. For multivariable analysis, ‘possible referrals' were grouped with ‘no action' for ovarian and oesophageal cancers because of small numbers.

Statistical analysis

We describe the primary-care interval distribution using the mean, median, 25th, 75th, and 90th centiles. Stratified by cancer diagnosis, we calculated the percentages of patients investigated by their GP in each of the five NICE CG27 referral recommendation groups. We calculated the mean difference in primary-care interval among those patients investigated in primary care and those who were not. To determine whether the association between primary-care investigations and primary-care interval can be attributed to different clinical presentations (i.e., whether patients who are most likely to be investigated are simply those who present with non-specific symptoms and have a longer primary-care interval for this reason), we used linear regression to estimate the mean difference in primary-care interval by investigation status, adjusting for age, gender, and the NICE referral category, separately by cancer. 95% Confidence intervals were estimated using bias corrected and accelerated bootstrap estimation, and where they exclude zero, the differences between the two groups were taken to be significant at P<0.05. Analyses were repeated for 99.99% confidence intervals. We performed a number of sensitivity analyses investigating the impact of how the primary-care interval, primary-care investigation use and clinical presentation were parameterised (see Appendix Tables for details). Further, we performed a supplementary analysis to explore the possibility that primary-care investigation may decrease the referral interval (defined as the number of days between referral from primary care and first patient contact in secondary care). We therefore explored the adjusted association of overall pre-hospital interval (defined as the total time from first presentation to primary care to first being seen in secondary care, i.e., referral interval plus primary-care interval) with investigation use.

Results

The derivation of the analysis sample is shown in Figure 1. In descriptive analyses, primary-care investigations were undertaken in 3198/5036 of included cases (64%), ranging from 43% for oesophageal cancer to 80% for lung cancer. The median primary-care interval across all six cancer sites was 16 (IQR 5–45) days for those who had one or more investigation, and 0 (IQR 0–10) days for those who had no investigation. The corresponding mean intervals were 41 days and 17 days, and did not differ by age or gender. The difference in the median interval by investigation status was considerably greater at the 75th (10 days non-investigated, 44 days investigated patients) and 90th centiles (45 days and 106 days, respectively) (Table 1).
Figure 1

Flow diagram: derivation of the analysis sample.

Table 1

Patient characteristics, mean and median (percentile) primary-care interval

 
 
Primary-care interval
 NMeanMedian25th Percentile75th Percentile90th Percentile
All
5036
32.5
8
0
34
87
Sex
Female241333.1903688
Male
2623
31.9
8
0
32
85
Age
15–4415036.97.5043113
45–5440530.3803475
55–64103031.1803385
65–74150332.0803483
75–84143033.6903688
85+
518
34.2
7
0
32
100
Cancer diagnosis
Colorectal211133.0603094
Ovarian34521.5702554
Lung149434.51333983
Oesophageal51326.3603175
Pancreatic32733.0703296
Stomach
246
43.2
13
0
58
132
Investigations in primary care
No183817.4001044
Yes319841.216545106
In unadjusted analyses, individual investigations lengthened the mean primary-care interval by between 5 days (chest X-ray) and 32 days (endoscopy), whereas undertaking more than one test in primary care added a mean of 8 days (Table 2). For individual cancer sites, any investigation significantly extended the mean primary-care interval by between 20 days (ovarian) and 30 days (stomach) (Table 2). When individual cancers were considered by NICE referral category, investigation was more likely if NICE CG27 mandated this or if no action was mandated. The proportion of patients presenting with symptoms for which NICE CG27 mandates urgent referral was 10%, 9%, 5%, 64%, 24%, and 37% for colorectal, ovarian, lung, oesophageal, pancreatic, and stomach cancer, respectively. Nevertheless, a substantial proportion of patients whose symptoms mandated urgent referral were investigated in primary care, ranging from 37% (oesophagus) to 75% (pancreas) (Table 3).
Table 2

Primary-care investigations and primary-care interval, by cancer

 
 
All
Colorectal
Ovarian
Lung
Oesophageal
Pancreatic
Stomach
  NMeanMedianNMeanMedianNMeanMedianNMeanMedianNMeanMedianNMeanMedianNMeanMedian
Any investigation in primary careNoa183817.4096718.601057.5029417.1129315.508115.509824.90
 
Yes
3198
41.2
16
1144
45.3
17
240
27.7
13
1200
38.9
16
220
40.7
21
246
38.8
13
148
55.3
22
Blood testNo299626.34114023.4119519.52105832.61135019.4112223013132.72
 
Yes
2040
41.6
15
971
44.4
16
150
24.1
13
436
39.5
17
163
41.2
21
205
39
12
115
55.2
21
Chest X-rayNo390831.46207033632721.1746431.9749425.9431431.5723942.812
 
Yes
1128
36.2
16
41
36.3
12
18
29.2
15.5
1030
35.8
15
19
37
27
13
68.9
39
7
56.6
19
UltrasoundNo454630.97197931.8518614.42145534.31349725.3521120.8321835.79
 
Yes
490
47.7
20
132
50.8
21.5
159
29.9
14
39
44.3
22
16
56.8
33
116
55.3
21
28
101.5
57
CT/MRINo492831.98209432.5633820.97142033.61251126.3632033.2724543.413
 
Yes
108
56.9
35
17
95.1
39
7
54.1
34
74
52.9
35
2
20.5
20.5
7
26
13
1
5
5
EndoscopyNo486131.48202231.1534121.77148434.41347825.1531430.8722243.512
 
Yes
175
63.1
20
89
76.7
20
4
7.5
7.5
10
56.4
40.5
35
43.2
15
13
86.7
49
24
40.5
19.5
Count of any of the above five investigations0a195219.5010312001088.3031222.4231517.708215.9010425.90.5
 1230138.71492342.41414730.11180937.71416237.31514822.97.511249.423
 2+78346.92115763.9239023.31437338.1203652.132.59763223079.821

Abbreviations: CT=computed tomography; MRI=magnetic resonance tomography.

The numbers in these two groups are slightly different as the first two rows include patients who have had any investigation in primary care, but the bottom three rows are counts based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).

Table 3

Use of primary-care investigations and the NICE guideline referral category based on clinical presentation, by cancer

 
 
 
GP investigations performed
 Action specified by NICE guidelines under NICE CG27 based on patient characteristics and clinical presentationAll NN%
ColorectalMandated referral under NICE guidelines (or good clinical practice)2089947.6
 Possible referral under NICE guidelines110558152.6
 Mandated investigation under NICE guidelines2009045.0
 Possible investigation under NICE guidelines0  
 
No action under NICE guidelines
598
374
62.5
OvarianMandated referral under NICE guidelines (or good clinical practice)311238.7
 Possible referral under NICE guidelines50 
 Mandated investigation under NICE guidelines261661.5
 Possible investigation under NICE guidelines0  
 
No action under NICE guidelines
283
212
74.9
LungMandated referral under NICE guidelines (or good clinical practice)763951.3
 Possible referral under NICE guidelines0  
 Mandated investigation under NICE guidelines22319587.4
 Possible investigation under NICE guidelines91677985.0
 
No action under NICE guidelines
279
187
67.0
OesophagealMandated referral under NICE guidelines (or good clinical practice)32812136.9
 Possible referral under NICE guidelines900.0
 Mandated investigation under NICE guidelines0  
 Possible investigation under NICE guidelines693652.2
 
No action under NICE guidelines
107
63
58.9
PancreaticMandated referral under NICE guidelines (or good clinical practice)795974.7
 Possible referral under NICE guidelines1006565.0
 Mandated investigation under NICE guidelines0  
 Possible investigation under NICE guidelines0  
 
No action under NICE guidelines
148
122
82.4
StomachMandated referral under NICE guidelines (or good clinical practice)924548.9
 Possible referral under NICE guidelines211571.4
 Mandated investigation under NICE guidelines0  
 Possible investigation under NICE guidelines402665.0
 No action under NICE guidelines936266.7

Abbreviations: GP=general practitioner; NICE=National Institute for Health and Care Excellence.

In linear regression analyses, stratified by cancer, that adjusted for age, sex, and the NICE referral category, adjustment for these factors explained very little of the mean observed additional days associated with investigation, but the effect for pancreatic cancer ceased to be significant (Table 4). Alternative parameterisations of the primary-care interval, investigation use, or clinical presentation categories made minimal difference to these findings (Appendix Tables A3–A5).
Table 4

Mean additional length of primary-care interval associated with primary-care investigations after adjustment for age, sex and NICE guideline referral category

 
 
 
Mean additional primary-care interval (in days) among patients where investigations were performed
 
  Number of casesUnadjustedAdjusted for age, sex, and clinical presentationP-valuea
ColorectalNot investigated967ReferenceReferenceP<0.0001
 
Investigated
1144
26.7 (20.8–33.0)
25.7 (19.5–31.7)
 
OvarianbNot investigated105ReferenceReferenceP<0.0001
 
Investigated
240
20.1 (13.6–27.5)
18.4 (12.2–25.5)
 
LungNot investigated294ReferenceReferenceP<0.0001
 
Investigated
1200
21.8 (15.3–27.6)
23.6 (16.8–30.0)
 
OesophagealbNot investigated293ReferenceReferenceP<0.0001
 
Investigated
220
25.3 (16.7–34.8)
22.3 (13.2–32.4)
 
PancreaticcNot investigated81ReferenceReferenceP>0.05
 
Investigated
246
23.2 (5.0–38.1)
17.1 (−1.9–30.6)
 
StomachNot investigated98ReferenceReferenceP<0.0001
 Investigated14830.4 (15.1–48.2)29.3 (14.0–45.8) 

Abbreviation: NICE=National Institute for Health and Care Excellence.

95% Confidence intervals were estimated using bias corrected and accelerated bootstrap. The P-value (P>0.05) presented for pancreatic cancer reflects that this 95% confidence interval crosses zero. For all other cancers bias corrected and accelerated bootstrap 99.99%confidence intervals were re-estimated for the same model and these also did not cross zero, P<0.0001 is correspondingly presented.

‘Possible referrals' grouped with ‘No action' in multivariable analysis because of small numbers.

Age 15–44 years grouped with age 55–64 years because of small numbers.

Among those patients for whom data on number of consultations prior to referral were available, 965/2095 (46.1%) of those consulting once were investigated, while 1058/1240 (85.3%) of those consulting 3+ times were investigated. Finally, in order to address the possibility that longer primary-care intervals might be offset by shorter referral intervals, we examined the association between investigations in primary care and the combined primary care and referral interval (i.e., from first presentation in primary care to first being seen in a specialist clinic). For all cancers, except pancreatic cancer, the pre-hospital interval is longer among investigated patients, compared with those who were not investigated. We find no evidence that longer primary-care intervals are offset by shorter referral intervals in patients who are investigated in primary care (Appendix Table A6). Because date of diagnosis did not form part of the data items collected for the audit, we were unable to examine the effect of investigations on total diagnostic interval.

Discussion

We found that for six specified cancers, investigation in primary care of the presenting symptom(s) was associated with later referral for specialist assessment. This difference in the mean primary-care interval ranged from an additional 20 to 30 days depending on the cancer site, and was independent of whether the patient presented with alarm symptoms. For four of the six cancers studied, the difference increased with the number of tests undertaken. The principle that patients with symptoms are initially assessed in primary care in order that only a proportion are then more extensively assessed by specialists (the gatekeeping function) is a key feature of health-care systems in which primary care features strongly. It contributes to their better health outcomes and efficiencies (Starfield ), although an ecological association with poorer cancer 1-year survival has also been described (Vedsted and Olesen, 2011). Investigation in primary care is most strongly associated with perceived medical need, although a minority of investigations are a consequence of patient preference (Little ). Where the alternative is specialist referral, investigation in primary care may result in the primary-care interval being prolonged, since additional consultations are needed to communicate results, and multiple consultations are associated with longer primary-care intervals (Lyratzopoulos ). We found that 85% of patients consulting three or more times had undergone investigation, compared with 46% of those consulting once. The literature is sparse on the effect of investigations in primary care on time to diagnosis, although a study of patients with colorectal cancer found that those who were not investigated by the faecal occult blood test had a significantly shorter median diagnostic interval than those who were (Hogberg ). Further, a qualitative study of patients with testicular cancer identified waiting time for GP-requested ultrasonography as a factor in late diagnosis (Chapple ). However, failure to investigate may be also associated with referral being deferred. In a study of GP-reported quality deviations in 5711 patients with cancer, failure to order relevant investigations was associated with a prolonged diagnostic interval (Jensen ), whereas diagnostic delay for tuberculosis has been associated with failure of the first doctor consulted to order a sputum test or chest X-ray (Calder ). Strategies have been developed to expedite the investigation of patients with symptoms that could indicate cancer. In Denmark, ambulatory care facilities exist for the prompt investigation of patients with non-specific symptoms, alongside an urgent referral pathway for those with higher-risk symptoms (Danish National Board of Health, 2010) Walk-in access to chest X-ray for symptomatic members of the public aged >50 years has been provided through a local initiative in Leeds, UK, resulting in 8.6% of all community-ordered chest X-rays being taken this way (Cheyne ). Dedicated centres that allow patients to access specialist assessment without physician referral have also been proposed by a panel of cancer experts in the United States, as a response to their Institute of Medicine report ‘Crossing the Quality Chasm' (Bowles ). The initiatives described address a range of constraints to prompt diagnosis, and they operate within complex health systems. Their impact can only be fully understood in the context of the overall diagnostic pathway, something we were unable to do in this study.

Strengths and limitations

This is the first study to explicitly determine the effect of GP-initiated investigations on speed of referral for specialist assessment. Its strengths include the relatively large number of cases for each cancer site, the completeness of data on presenting symptom(s) and consultations, and the direct extraction of information from the primary-care record. The study team included experienced clinicians, ensuring that the complex task of coding clinical data was accurately completed. There are several limitations that we acknowledge. Because participation of general practices in the audit was voluntary and potentially biased towards those most interested in cancer care, the findings may represent ‘better' practice. However, the audit patient population was similar to the incident cancer cases in England (Rubin ) while the characteristics of participating practices were similar to non-participating practices of the same (former) cancer network (Lyratzopoulos ). Nevertheless, these practices may have been more interested in cancer diagnosis and management and more likely to investigate patients with suspicious symptoms. Practices were typically required to audit a continuous sample of cases occurring in a specified period, and there was no evidence of significant exclusion of cases (Rubin ). Data were extracted from clinical records and hospital correspondence. There was no validation of the data, but in all cases data were reviewed at a practice meeting and checked for completeness and face validity by a cancer network clinical lead. There is scope for errors of interpretation during data extraction, for example, in deciding on the date of first consultation. The potential sources of error in studies of diagnostic intervals have been well described (Weller ), but the methodology used by the audit conformed to best practice in the field Weller ). Finally, 1100 (17.9%) cases were excluded because both of the dates required to estimate the primary-care interval were not available. Many of these were patients whose pathway to diagnosis bypassed primary care, for example, through direct presentation to an emergency department. Others may have been seen by the GP, but the omission of dates of the first encounter and/or referral was not identified during the checking process prior to submission of data to the audit. All investigations included were part of the primary-care appraisal process, but no judgement was made on their appropriateness or their context within the episode of care. It is possible that some were unhelpful or irrelevant to the diagnostic process and unnecessarily prolonged the primary-care interval. Details of the precise nature of blood or urine tests or the sites examined by CT, MRI, or endoscopy were not a specific requirement of practices participating in the audit. Because the audit data were provided in an anonymous form, we were unable to link them to cancer registration and hospital record-derived data. This would have allowed us to determine, for those patients not investigated in primary care, whether investigation(s) were then undertaken in secondary or tertiary care and the effect of investigations in different settings on the total diagnostic interval. However, we observed that use of investigations, although adding to the length of the primary-care interval, did not result in a shorter referral interval. Moreover, for the hypothesis to be true that patients investigated in primary-care experience shorter secondary-care delays, and therefore no overall lengthening of the total diagnostic interval, either or both of the referral interval and the within-hospital interval to diagnosis would need to be substantially shorter for those patients with primary-care investigations compared with those without. These conditions are unlikely. First, we have observed a net lengthening of referral interval resulting from investigations for five out of six cancers. Second, as use of investigations is associated with extending of the primary-care interval by a median of +16 days and a mean of +24 days, within-hospital diagnostic processes would need to be extraordinarily fast to compensate for these prolonged intervals. It should also be noted that in 2011/12 87.3% of patients commenced treatment within 62 days of referral, and 98.4% commenced treatment within 31 days of a diagnosis being made (Department of Health, 2012b). Moreover, the most frequent primary-care investigations were blood tests and chest X-rays, tests that do not typically provide the definitive diagnostic information necessary to establish the diagnosis of cancer, and would be unlikely to result in any substantial shortening of diagnostic intervals within secondary or tertiary care. We selected the NICE referral category as our primary method for categorising patients' presenting symptoms. We adjusted for symptom status using a range of complementary analytical approaches, all of which indicated that the degree of confounding by symptom status (in respect of the association between investigation and prolonged primary-care interval) is trivial. In other words, whether patients present with non-specific symptoms or obvious alarm symptoms, investigations are always associated with a longer primary-care interval.

Implications for practice

Our findings are generalisable to health systems in which GPs act as gatekeepers to specialist care, but may be modified by differences in access to diagnostic tests. A substantial proportion of patients underwent investigation when their symptoms fulfilled NICE CG27 criteria for urgent referral. There are several possible explanations for this. Disparaging views from specialists about ‘abuse' by GPs of the urgent referral pathway may make some prefer to have additional evidence in the form of a confirmatory test result before making a referral (Mathew and Desai, 2009). The NICE criteria typically represent a risk of cancer in the region of 5–10%, the large majority not having the disease, and some GPs may use investigations as means of increasing the probability of cancer prior to making a decision about referral. It is also possible that some patients present in a context that causes the GP to modify their preferred course of action. For example, the patient may have been investigated in the past for the same problem, have severe co-morbidities, or may be reluctant to be referred to a specialist. Some GPs may consider it desirable, or have been advised that it is, for the results of baseline investigations to be available at the first specialist attendance (Barking, Havering and Redbridge University Hospital, 2014). Significant event analyses and case-note review studies are required to further establish the circumstances surrounding such ‘guideline violations' (Mitchell ; Singh ). Finally, certain investigations available to GPs are the definitive diagnostic tests, e.g., gastroscopy for suspected oesophagogastric cancer, and may be as readily available in primary as in specialist care. Other diagnostic tests, however, take longer to complete when ordered from primary care and may not be sufficiently comprehensive. In England, the median time from request to test for non-obstetric ultrasound investigation is longer for GP requests (19–27 days) than for all request sources combined (12–16 days) (NHS England, 2013). If investigations are undertaken in patients for whom urgent referral is indicated, the request should be concurrent with referral. Because tests ordered in primary care may not be done or reported as promptly as those ordered from secondary care, our findings point to a need for investigative services to be provided to a comparable standard regardless of source of request. This should be accompanied by improved systems in primary care that ensure that a patient is rapidly reviewed once results are received. They also provide some support for models of service delivery in England that permit the rapid specialist assessment of patients with lower-risk symptoms, either by a lowering of the thresholds for urgent (2 weeks) referral for suspected cancer or the provision of diagnostic centres. Time may be used as a diagnostic tool in primary care (Heneghan ). Symptoms are seen by GPs at an earlier stage of development than in secondary care, and time allows the clinician to observe whether relatively undifferentiated symptoms develop more specific characteristics or resolve spontaneously. Investigations may form a part of this temporising approach while also being part of a safety-netting strategy (Almond ). These findings are the first step in determining the most effective diagnostic strategies for managing patients with symptomatic presentation of cancer. It will be important to understand the impact of primary-care investigation on secondary-care intervals, since these may plausibly be shortened, and on total diagnostic delay. Until then, no firm recommendations can be made on the merits or demerits of primary-care investigation. There is a need to understand the comparative clinical and health economic efficiency of strategies that encourage early primary-care investigation, compared with those that encourage either expectant management with limited testing and urgent referral if symptoms persist or worsen, or early referral without prior investigation.
Table A1

Symptom groups by cancer

Oesophageal and gastric cancerLung cancerOvarian cancerColorectal cancerPancreatic cancer
Dysphagia
Haemoptysis
Ultrasound suggestive of ovarian cancer
Rectal bleeding
Obstructive jaundice
Early satiety
Chest/shoulder pain
Post-menopausal bleeding
Altered bowel habit (to looser stool)
Thromboembolic disease
Nausea, vomiting
Dyspnoea
Persistent intermenstrual bleeding (with a negative pelvic examination)
Abdominal mass
Bleeding per rectum/melaena
Dyspepsia
Weight loss
Abdominal or pelvic mass not of gastroenterological or urological origin
Rectal mass
Diabetic ketoacidosis/new onset diabetes/loss of known diabetes control
Reflux
Chest signs
Abdominal or pelvic pain or discomfort
Anaemia
Altered bowel habit
Pain (epigastric, abdominal, chest)
Hoarseness
Abdominal bloating/distension/swelling/fullness
Weight loss
Nausea and vomiting
Anorexia
Clubbing
Urinary symptoms (including incontinence and retention)
Abdominal pain or tenderness
Gastro-oesophageal reflux disease
Fatigue, malaise
Chest X-ray/supraclavicular lymph nodes
Unexplained weight loss
Bloating/distension
General malaise
Weight loss
Cough
Fatigue/tiredness/malaise/unwell/exhaustion
Malaise
Bloating
Bowel disturbance
Features suggesting metastases
Change in bowel habit to diarrhoea or alternating diarrhoea/constipation
Asymptomatic or incidental, including surveillance
Biliary colic
Iron deficiency anaemia
Abnormal chest X-ray
 
Acute surgical/medical emergency
Cough/shortness of breath
Haematemesis/melaena
Superior vena cava obstruction
Vaginal discharge or other abnormal vaginal bleeding
Constipation
Weight loss
Dizziness
Stridor
Anaemia
Nausea/vomiting
Urinary tract infection/other urinary symptoms
Upper abdominal mass
Loss of appetite
Chest symptoms
Other pain
anaemia
Asymptomatic or incidental finding
Thrombocytosis
Pulmonary embolus or deep vein thrombosis
Defaecation problems
Back pain
Pain (other)
Abnormal spirometry
Infertility
Anorexia
Abdominal pain
Barrett's
Asymptomatic or incidental
Nausea and/or vomiting
Mucus
Abdominal mass
Respiratory symptoms
Hyponatraemia
Asymptomatic or incidental
Collapse
Asymptomatic or incidental
Bloating
Respiratory infection
Ascites
Respiratory symptoms
Anorexia
Belching
Exacerbation of chronic obstructive pulmonary disease
Anorexia
Haemorrhoids
Dysphagia
Throat symptoms
Abdominal pain
Other/missing/not stated/not known
Urinary symptoms
Change in bowel habit
Hiatus hernia
Back pain
 
Liver
Dyspepsia
Odynophagia
Liver symptoms/signs
 
Upper gastrointestinal symptoms
 
Other/missing/not stated/not known
Confusion
 
Disordered sensation lower limbs
Liver
 
Malaise
 
Ascites
Pancreatitis/chronic
 
Collapse
 
Colitis/inflammatory bowel disease
Steatorrhoea
 
Change in bowel habit
 
Other/missing/not stated/not known
Lymphadenopathy
 
Pain (other)
 
 
Other/missing/not stated/not known
 
Urinary symptoms
 
 
 
 
Headache
 
 
 
 
Lower limb oedema
 
 
 
 
Sweats/fever
 
 
 
 
Anaemia
 
 
 
 
Upper gastrointestinal symptoms
 
 
 
 
Lump
 
 
 
 
Nausea or vomiting
 
 
 
 
Cardiac abnormalities
 
 
 
 
Neurological
 
 
 
 
ENT symptoms
 
 
 
 Other/missing/not stated/not known   

Abbreviation: ENT=ear, nose and throat.

Table A2

NICE guideline referral categories based on clinical presentation

Mandated referral under NICE guidelines (or good clinical practice)
Clear evidence for mandated urgent referral as per NICE CG27
 Good clinical medicine would mandate urgent referral
Possible referral under NICE guidelinesPossible mandated urgent referral as per NICE CG27—but duration dependent
 Possible mandated urgent referral as per NICE CG27—but severity dependent
 Possible mandated urgent referral as per NICE CG27—but location dependent
 Possible mandated urgent referral as per NICE CG27—but dependent upon sense of abnormality
 
Possible mandated urgent referral as per NICE CG27—other
Mandated investigation under NICE guidelines
Clear evidence of mandated investigation as per NICE CG27
Possible investigation under NICE guidelinesPossible mandated investigation as per NICE CG27—but duration dependent
 Possible mandated investigation as per NICE CG27—but severity dependent
 Possible mandated investigation as per NICE CG27—but location dependent
 Possible mandated investigation as per NICE CG27—but dependent upon sense of abnormality
 
Possible mandated investigation as per NICE CG27—other
No action under NICE guidelinesNo mandated action from NICE CG27

Abbreviation: NICE=National Institute for Health and Care Excellence.

Table A3

Sensitivity analysis using alternative parameterisation of primary-care interval

  Number of casesAdjusted for age, sex, and the NICEreferral category based on presenting symptomsOR (95% CI) for 15+ days primary-care interval (compared with 0–14 days) adjusted for age, sex, and clinical presentationP-value
ColorectalNot investigated967ReferenceReference<0.001
 
Investigated
1144
25.7 (19.5–31.7)
4.6 (3.7–5.6)
 
OvarianNot investigated105ReferenceReference<0.001
 
Investigated
240
18.4 (12.2–25.5)
4.2 (2.3–7.9)
 
LungNot investigated294ReferenceReference<0.001
 
Investigated
1200
23.6 (16.8–30.0)
3.8 (2.8–5.2)
 
OesophagealNot investigated293ReferenceReference<0.001
 
Investigated
220
22.3 (13.2–32.4)
4.1 (2.8–6.1)
 
PancreaticNot investigated81ReferenceReference<0.001
 
Investigated
246
17.1 (−1.9–30.6)
4.4 (2.1–9.2)
 
StomachNot investigated98ReferenceReference<0.001
 Investigated14829.3 (14.0–45.8)5.7 (3.1–10.6) 

Abbreviations: CI=confidence interval; NICE=National Institute for Health and Care Excellence; OR=odds ratio.

Results presented in bold italics are those from Table 4

This sensitivity analysis finds that investigation use is associated with longer primary-care interval for all six cancers when using a logistic model.

Table A4

Sensitivity analysis using alternative parameterisation of investigation use in primary care

  Number of casesAdjusted for age, sex, and the NICE referral category based on presenting symptoms Number of casesAdjusted for age, sex, and the NICE referral category based on presenting symptoms
ColorectalNot investigateda967ReferenceNo investigationsa1031Reference
 Investigated114425.7 (19.5–31.7)One92321.3 (15.1–30.0)
 
 
 
 
Two+
157
43.5 (28.3–58.2)
OvarianNot investigated105ReferenceNo investigations108Reference
 Investigated24018.4 (12.2–25.5)One14720.1 (11.0–30.6)
 
 
 
 
Two+
90
13.6 (6.0–21.2)
LungNot investigated294ReferenceNo investigations312Reference
 Investigated120023.6 (16.8–30.0)One80917.0 (6.9–24.7)
 
 
 
 
Two+
373
16.2 (6.6–24.8)
OesophagealNot investigated293ReferenceNo investigations315Reference
 Investigated22022.3 (13.2–32.4)One16217.1 (7.7–28.8)
 
 
 
 
Two+
36
29.9 (10.3–58.1)
PancreaticNot investigated81ReferenceNo investigations82Reference
 Investigated24617.1 (−1.9–30.6)One1484.8 (−14.4–16.7)
 
 
 
 
Two+
97
41.3 (20.2–62.5)
StomachNot investigated98ReferenceNo investigations104Reference
 Investigated14829.3 (14.0–45.8)One11221.2 (6.2–35.8)
    Two+3056.0 (16.7–107.8)

Abbreviations: CT=computed tomography; MRI=magnetic resonance tomography; NICE=National Institute for Health and Care Excellence.

aThe numbers in these two groups (for all cancers) are slightly different as column 3 includes patients who have had any investigation in primary care, but counts in column 6 are based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).

Results presented in bold italics are those from Table 4

With a single exception (pancreatic cancer) primary-care investigations were associated with longer primary-care intervals. For colorectal, oesophageal, pancreatic and stomach cancer, primary-care intervals were longer among people who had two or more primary-care investigations, compared with those who had one. For lung and ovarian cancer. investigation use was associated with longer primary-care interval, but delay was not additionally longer among people with two or more primary-care investigations, compared with only one.

Table A5

Sensitivity analysis using alternative parameterisation of clinical presentation (symptom category) or the NICE referral category

  Number of casesAdjusted for age, sex, and main (5) NICE referral categories based on presenting symptomsAdjusting for age and sex and detailed (14) NICE referral categoriesAdjusting age and sex and for clinical presentation using main presenting symptomAdjusting for age and sex and for clinical presentation using main presenting symptom (allowing the effect of symptom to vary by age)
ColorectalNot investigated967ReferenceReferenceReferenceReference
 
Investigated
1144
25.7 (19.5–31.7)
24.6
26.5
26.2
OvarianNot investigated105ReferenceReferenceReferenceReference
 
Investigated
240
18.4 (12.2–25.5)
18.5
17.8
18.1
LungNot investigated294ReferenceReferenceReferenceReference
 
Investigated
1200
23.6 (16.8–30.0)
23.9
20.1
20.8
OesophagealNot investigated293ReferenceReferenceReferenceReference
 
Investigated
220
22.3 (13.2–32.4)
22.7
23.4
23.0
PancreaticNot investigated81ReferenceReferenceReferenceReference
 
Investigated
246
17.1 (−1.9–30.6)
14.9
13.9
16.0
StomachNot investigated98ReferenceReferenceReferenceReference
 Investigated14829.3 (14.0–45.8)28.427.728.0

Abbreviation: NICE=National Institute for Health and Care Excellence.

Results presented in bold italics are those from Table 4.

Different approaches to adjusting for clinical presentation in different ways have minimal impact on the association between primary-care investigation use and primary-care interval.

Table A6

Supplementary analysis. The association between investigation use and referral interval (defined as period from day of referral to day when patient was first seen at hospital)

 
 
Primary-care interval
Referral interval
Pre-hospital interval
  Number of casesAdjusted for age, sex, and the NICE referral category of presenting symptomsNumber of casesAdjusted for age, sex, and the NICE referral category of presenting symptomsNumber of casesAdjusted for age, sex, and the NICE referral category of presenting symptoms
ColorectalNot investigated967Reference946Reference946Reference
 
Investigated
1144
25.7 (19.5–31.7)
1120
5.1 (2.1–8.7)
1120
28.4 (21.9–34.9)
OvarianNot investigated105Reference101Reference101Reference
 
Investigated
240
18.4 (12.2–25.5)
236
1.6 (−5.0–4.6)
238
18.7 (10.0–27.4)
LungNot investigated294Reference290Reference290Reference
 
Investigated
1200
23.6 (16.8–30.0)
1165
4.5 (−1.6–10.1)
1165
28.6 (19.4–36.8)
OesophagealNot investigated293Reference283Reference283Reference
 
Investigated
220
22.3 (13.2–32.4)
215
4.5 (−2.2–13.3)
215
29.1 (18.2–42.5)
PancreaticNot investigated81Reference78Reference78Reference
 
Investigated
246
17.1 (−1.9–30.6)
241
−9.4 (−33.2–3.1)
241
7.4 (−15.6–30.3)
StomachNot investigated98Reference95Reference95Reference
 Investigated14829.3 (14.0–45.8)14111.9 (5.1–26.7)14141.8 (21.5–63.4)

Abbreviation: NICE=National Institute for Health and Care Excellence.

Results presented in bold italics are those from Table 4.

  26 in total

1.  Effect of a practice-based strategy on test ordering performance of primary care physicians: a randomized trial.

Authors:  Wim H J M Verstappen; Trudy van der Weijden; Jildou Sijbrandij; Ivo Smeele; Jan Hermsen; Jeremy Grimshaw; Richard P T M Grol
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 2.  Contribution of primary care to health systems and health.

Authors:  Barbara Starfield; Leiyu Shi; James Macinko
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

3.  Diagnostic safety-netting.

Authors:  Susanna Almond; David Mant; Matthew Thompson
Journal:  Br J Gen Pract       Date:  2009-11       Impact factor: 5.386

4.  Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study.

Authors:  Peter Vedsted; Frede Olesen
Journal:  Br J Gen Pract       Date:  2011-08       Impact factor: 5.386

Review 5.  Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis.

Authors:  Petra Jellema; Daniëlle A W M van der Windt; David J Bruinvels; Christian D Mallen; Stijn J B van Weyenberg; Chris J Mulder; Henrica C W de Vet
Journal:  BMJ       Date:  2010-03-31

6.  Types and origins of diagnostic errors in primary care settings.

Authors:  Hardeep Singh; Traber Davis Giardina; Ashley N D Meyer; Samuel N Forjuoh; Michael D Reis; Eric J Thomas
Journal:  JAMA Intern Med       Date:  2013-03-25       Impact factor: 21.873

7.  Understanding diagnosis of lung cancer in primary care: qualitative synthesis of significant event audit reports.

Authors:  Elizabeth D Mitchell; Greg Rubin; Una Macleod
Journal:  Br J Gen Pract       Date:  2013-01       Impact factor: 5.386

8.  An audit of urology two-week wait referrals in a large teaching hospital in England.

Authors:  Anup Mathew; K M Desai
Journal:  Ann R Coll Surg Engl       Date:  2009-04-02       Impact factor: 1.891

9.  Importance of patient pressure and perceived pressure and perceived medical need for investigations, referral, and prescribing in primary care: nested observational study.

Authors:  Paul Little; Martina Dorward; Greg Warner; Katharine Stephens; Jane Senior; Michael Moore
Journal:  BMJ       Date:  2004-02-13

10.  Understanding high-quality cancer care: a summary of expert perspectives.

Authors:  Erin J Aiello Bowles; Leah Tuzzio; Cheryl J Wiese; Beth Kirlin; Sarah M Greene; Steven B Clauser; Edward H Wagner
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

View more
  17 in total

Review 1.  Improving early diagnosis of symptomatic cancer.

Authors:  Willie Hamilton; Fiona M Walter; Greg Rubin; Richard D Neal
Journal:  Nat Rev Clin Oncol       Date:  2016-07-26       Impact factor: 66.675

2.  Responsibility for follow-up during the diagnostic process in primary care: a secondary analysis of International Cancer Benchmarking Partnership data.

Authors:  Brian D Nicholson; Clare R Goyder; Clare R Bankhead; Berit S Toftegaard; Peter W Rose; Hans Thulesius; Peter Vedsted; Rafael Perera
Journal:  Br J Gen Pract       Date:  2018-04-23       Impact factor: 5.386

3.  Potential for Reducing Time to Referral for Colorectal Cancer Patients in Primary Care.

Authors:  Nicole F van Erp; Charles W Helsper; Saskia M Olyhoek; Ramon R T Janssen; Amber Winsveen; Petra H M Peeters; Niek J de Wit
Journal:  Ann Fam Med       Date:  2019-09       Impact factor: 5.166

Review 4.  Reimagining the diagnostic pathway for gastrointestinal cancer.

Authors:  Greg Rubin; Fiona Walter; Jon Emery; Niek de Wit
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-02-07       Impact factor: 46.802

5.  Direct access cancer testing in primary care: a systematic review of use and clinical outcomes.

Authors:  Claire Friedemann Smith; Alice C Tompson; Nicholas Jones; Josh Brewin; Elizabeth A Spencer; Clare R Bankhead; Fd Richard Hobbs; Brian D Nicholson
Journal:  Br J Gen Pract       Date:  2018-08-13       Impact factor: 5.386

6.  Pre-referral GP consultations in patients subsequently diagnosed with rarer cancers: a study of patient-reported data.

Authors:  Silvia C Mendonca; Gary A Abel; Georgios Lyratzopoulos
Journal:  Br J Gen Pract       Date:  2016-03       Impact factor: 5.386

7.  Preventing delayed diagnosis of cancer: clinicians' views on main problems and solutions.

Authors:  Lorainne Tudor Car; Nikolaos Papachristou; Catherine Urch; Azeem Majeed; Mona El-Khatib; Paul Aylin; Rifat Atun; Josip Car; Charles Vincent
Journal:  J Glob Health       Date:  2016-12       Impact factor: 4.413

8.  Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma.

Authors:  Heidi Buvarp Dyrop; Peter Vedsted; Mathias Rædkjær; Akmal Safwat; Johnny Keller
Journal:  Acta Orthop       Date:  2017-01-12       Impact factor: 3.717

9.  Are Regulations Safe? Reflections From Developing a Digital Cancer Decision-Support Tool.

Authors:  Ciarán D McInerney; Beverly C Scott; Owen A Johnson
Journal:  JCO Clin Cancer Inform       Date:  2021-03

10.  Variation in Direct Access to Tests to Investigate Cancer: A Survey of English General Practitioners.

Authors:  Brian D Nicholson; Jason L Oke; Peter W Rose; David Mant
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.